Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Pulmonx (NASDAQ:LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4 at 1:30 PM PT in Boston, with a webcast available. Additionally, management will attend the Lake Street Best Ideas Growth Conference on September 11 in New York for one-on-one meetings. Investors can access the Wells Fargo fireside chat webcast through Pulmonx's investor relations website.
Pulmonx (Nasdaq: LUNG) reported its Q2 2025 financial results, achieving total revenue of $23.9 million, representing a 15% year-over-year increase. The company's performance was driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).
The company maintained a gross margin of 72% but reported a net loss of $15.2 million ($0.38 per share). Due to slower-than-expected U.S. revenue conversion, Pulmonx revised its full-year 2025 guidance down to $90-92 million from the previous $96-98 million forecast. Operating expenses are now expected to be $128-130 million, reduced from prior guidance of $133-135 million.
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has scheduled its Q2 2025 financial results announcement for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live and archived webcast through the company's investor relations website.
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference. The presentation is scheduled for June 11, 2025, at 7:00 AM PT / 10:00 AM ET in Miami. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET in Las Vegas. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx (Nasdaq: LUNG) reported strong Q1 2025 financial results, achieving worldwide revenue of $22.5 million, marking a 20% increase year-over-year. The company's performance was driven by both domestic and international growth, with U.S. revenue reaching $14.2 million (11% increase) and international revenue hitting $8.3 million (39% increase).
Key financial metrics include:
- Gross margin of 73%
- Operating expenses of $30.9 million
- Net loss of $14.4 million ($0.36 per share)
- Cash and equivalents totaling $88.7 million
The company reaffirmed its 2025 revenue guidance of $96-98 million and expects a gross margin of approximately 74%. Operating expenses are projected between $133-135 million, including $22 million in stock-based compensation. The U.S. Department of Justice has declined to intervene in a case against Pulmonx and concluded its civil investigative demand.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025.
The company will host a conference call with management to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the earnings call through the investor relations section of Pulmonx's website.
Pulmonx (NASDAQ: LUNG) reported strong financial results for Q4 and full year 2024. The company achieved record worldwide revenue of $83.8 million for FY2024, up 22% year-over-year, and Q4 2024 revenue of $23.8 million, a 23% increase from Q4 2023.
U.S. revenue reached $56.5 million for FY2024 (23% growth) and $15.9 million for Q4 2024 (16% growth). The company maintained a gross margin of 74% throughout 2024. Net loss for FY2024 improved to $56.4 million ($1.44 per share) compared to $60.8 million ($1.60 per share) in 2023.
For 2025, Pulmonx projects revenue between $96-98 million (15-17% growth) and expects to maintain a 74% gross margin. Operating expenses are forecasted at $133-135 million, including $22 million in stock-based compensation.
Pulmonx (Nasdaq: LUNG), a pioneer in minimally invasive treatments for severe lung disease, has announced its participation in an upcoming investor event. The company will engage in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on February 27, 2025, at 8:00 AM PT / 11:00 AM ET.
Interested parties can access both live and archived versions of the presentation through the 'Investors' section of the Pulmonx website at investors.pulmonx.com.